ClinicalTrials.gg
CompletedNCT05807490Updated Jul 19, 2024

A Study to Learn How Different Amounts of the Study Medicine Called PF-07328948 Are Tolerated and Act in the Body in Healthy Adults

A Phase 1 interventional study of PF-07328948 and Placebo in Healthy, sponsored by Pfizer. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-07-19.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 4 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study has two parts: Part A and Part B.

The purpose of Part A of this study is to learn about the safety, tolerability, and how PF-07328948 is processed by the body when multiple doses of PF-07328948 are given to healthy participants.

The purpose of Part B of this study is to understand the amount of PF-07328948 that would be available in the body after taking a single pill. The amount will be compared to the amount of PF-07328948 in a suspension in healthy adults.

Part B will be conducted if the results of Part A support further study of PF-07328948.

The study is seeking participants who:

  • are females who are not able to give birth to a child of 18 years of age or older.
  • are males of 18 years of age or older.
  • have a BMI of 20.0 to 35.0 kg/m2.
  • have total body weight of more than 50 kg (110 lbs).

Participants in Part A will be randomly selected to receive either PF-07328948 or placebo (a pill that has no medicine in it).

Participants in Part B will receive PF-07328948 as suspension and tablet form, both taken by mouth after food or during fasting.

For a given participant in Part A, the total study is going to last up to about 12 weeks. This includes from the time of selection till the last follow-up phone call. The participants will be selected if they are fit for the study 28 days before the first dose of the study medicines. Participants who are selected will be admitted to the study site on Day -2 for around 19 days. Following discharge, participants will return for an on-site follow-up visit 7 to 10 days after receiving the final dose of the study medicine. The follow-up contact may be via a telephone call and will happen 28 to 35 days after the final dose of study medicine is given.

For a given participant in Part B, the total study is going to last up to about 10-12 weeks. Participants will stay overnight at the CRU for 23 days (Sequence 1) or 18 days (Sequence 2), starting with check-in. In Sequence 1, there will be a minimum of 10 days between doses in Period 1 and 2, and at least 7 days between doses in Period 2 and Period 3. In Sequence 2, there will be a minimum of 7 days between each dose.

02

Conditions studied

  • Healthy

Keywords

  • PF-07328948
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Female participants of non- and males must be 18 to 60 years of age for Part A and 18 to 65 years of age for Parts B at the time of signing the ICD, overtly healthy as determined by medical evaluation including medical history, physical exam, laboratory tests, and cardiac monitoring.
  2. of 20.0 to 35.0 kg/m2 and a total body weight >50 kg (110 lbs) for Part A. BMI of 17.5 to 35.0 kg/m2 and a total body weight >50 kg (110 lbs) for Part B.
  3. Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
  4. Capable of giving signed , which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological (including prothrombic/coagulopathic states), renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).

    • Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).
    • History of infection, , or ; positive testing for HIV, HBsAg, HBcAb, or HCVAb. Hepatitis B vaccination is allowed.
  2. Part B only: History of irregular bowel movements including irritable bowel syndrome or frequent episodes of diarrhea or constipation (defined as less than 1 bowel movement on average every 2 days) or lactose intolerance.
  3. Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality or other conditions or situations related to COVID-19 pandemic that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  4. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.
  5. Receipt of a COVID-19 vaccine within 7 days before screening or within 7 days before any visit in which a safety lab is planned. Vaccination with a COVID 19 vaccine that occurs greater than 7 days from either screening or any visit in which a safety lab is planned is permitted.
  6. Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  7. Evidence of a prothrombotic state as evidenced by any of the following:

    • History of DVT, pulmonary embolism or arterial thrombosis.
    • Known genetic predisposition (Factor V Leiden, prothrombin G20210A, Protein C/S deficiency, antithrombin deficiency) based on medical history. Genetic testing at screening is not required.
    • ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test if deemed necessary:
    • presence of anti-phospholipid antibodies ("Positive" lab result for anticardiolipin, IgA, IgG or IgM)
    • Protein C activity \< LLN of laboratory reference range
    • Protein S activity \< LLN of laboratory reference range
    • Free Protein S antigen \< LLN of laboratory reference range
    • Antithrombin activity \< LLN of laboratory reference range
    • Positive test for APC resistance (Resistance Ratio \< LLN of laboratory reference range)
    • Plasma fibrinogen > of laboratory reference range
    • D-dimer ≥ 500 ng/ml (≥ 0.50 ug/ml)
  8. A positive urine drug test.
  9. Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest.
  10. Renal impairment as defined by an \<75 mL/min/1.73m2 calculated using CKD EPI SCr formulas.
  11. Standard 12-lead that demonstrates clinically relevant abnormalities that may affect participant safety or interpretation of study results (eg, >450 ms, complete LBBB, signs of an acute or indeterminate age myocardial infarction, STT interval changes suggestive of myocardial ischemia, second- or third-degree AV block, or serious bradyarrhythmias or tachyarrhythmias). If the uncorrected QT interval is >450 ms, this interval should be rate corrected using the Fridericia method only and the resulting QTcF should be used for decision-making and reporting.
  12. Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study specific laboratory and confirmed by a single repeat test, if deemed necessary:

    • or ALT level ≥1.5× ULN;
    • Total level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ULN.
  13. Prior exposure to PF-07328948.
  14. History of alcohol abuse or binge drinking and/or any other illicit drug use or dependence within 6 months of Screening. Binge drinking is defined as a pattern of 5 (male) and 4 (female) or more alcoholic drinks in about 2 hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit, or 3 ounces (90 mL) of wine).
  15. Investigator site staff directly involved in the conduct of the study and their family members, site staff otherwise supervised by the investigator, and sponsor and sponsor delegate employees directly involved in the conduct of the study and their family members.
  16. Use of tobacco or nicotine-containing products in excess of the equivalent of 5 cigarettes/day or 2 chews of tobacco/day.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
86 participants (actual)

Study arms

  • Experimental
    PF-07328948 and Placebo (Cohort 1)

    Dose level 1: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 2)

    Dose level 2: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 3)

    Dose level 3: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 4)

    Dose level 4: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 5)

    Dose level 5: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 10)

    Optional cohort - Multiple dose administration of PF-07328948 and placebo over 14 days in healthy Japanese participants; 5 participants will receive PF-07328948 and 1 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 7)

    Dose level 7: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 8)

    Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 oral tablet and oral suspension (Cohort 11)

    Assessment of relative bioavailability PF-07328948 oral tablet compared to PF-07328948 oral suspension under fed and fasted condition; 12 participants will be enrolled, and 6 participants randomized to 1 of 2 sequences

    Drug: PF-07328948

  • Experimental
    PF-07328948 and Placebo (Cohort 6)

    Dose level 6: Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

  • Experimental
    PF-07328948 and Placebo (Cohort 9)

    Optional cohort - Dose level TBD. Multiple dose administration of PF-07328948 and placebo over 14 days in healthy participants; 8 participants will receive PF-07328948 and 2 will receive placebo

    Drug: PF-07328948 · Drug: Placebo

Interventions

  • PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions BID over 14 days

  • PF-07328948 will be administered as oral suspensions daily (QD) over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions every QD over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions QD over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions QD over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days

  • PF-07328948 will be administered as oral suspensions QD over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

  • Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition

  • PF-07328948 will be administered as oral suspensions QD over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions QD over 14 days

  • PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

  • DrugPlacebo

    Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

  • PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Time frame: Baseline up to 35 days after last dose of study intervention (approximately 11 weeks)

  2. Part A: Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks).

  3. Part A: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)

  4. Part A: Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings

    Time frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)

  5. Part A: Number of Participants With Change From Baseline in Physical Examination Findings

    Time frame: Baseline up to 10 days after last dose of study intervention (approximately 7 weeks)

  6. Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry

    Time frame: 0 to 8 hours post-dose on Day 1

  7. Part A: Number of Participants With Cardiac Rhythms of Potential Clinical Concern Assessed By Telemetry

    Time frame: 0 to 8 hours post-dose on Day 14

  8. Part B: Maximum Observed Plasma Concentration (Cmax) of PF-07328948 Tablet Formation and Oral Suspension

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

  9. Part B: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07328948 Tablet Formation and Oral Suspension

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

  10. Part B: Area Under the Plasma Concentration-time Curve from Time 0 to Extrapolated Infinite Time (AUCinf) of PF-07328948 Tablet Formation and Oral Suspension

    Time frame: Predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 1

  2. Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 14

  3. Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (tau) (AUCtau) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 1

  4. Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (tau) (AUCtau) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 14

  5. Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 1

  6. Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07328948

    Time frame: predose, 0.25, 0.5, 1, 1.5, 2, 4, 8, 12, 24, 36, 38, and 72 hours post dose on Day 14

  7. Part A: Amount of PF-07328948 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)

    Time frame: On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-12 hours for 12 hour dosing interval; 0-24 hours for 24 hour dosing interval)

  8. Part A: Percentage of Dose of PF-07328948 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)

    Time frame: On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-12 hours for 12 hour dosing interval; 0-24 hours for 24 hour dosing interval)

  9. Part A: Renal Clearance of PF-07328948

    Time frame: On Day 14, urine collection for PK to occur over 0-tau, according to dosing frequency (ie, 0-12 hours for 12 hour dosing interval; 0-24 hours for QD dosing interval)

  10. Part B: Maximum Observed Plasma Concentration (Cmax) of PF-07328948 Tablet Formation Under Fasted and Fed Condition

    Time frame: predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

  11. Part B: Area Under the Plasma Concentration-time Curve from Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of PF-07328948 Tablet Formation Under Fasted and Fed Condition

    Time frame: predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

  12. Part B: Area Under the Plasma Concentration-time Curve from Time 0 to Extrapolated Infinite Time (AUCinf) of PF-07328948 Tablet Formation Under Fasted and Fed Condition

    Time frame: predose, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, and 72 hours post dose on Day 1

  13. Part B: Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs)

    Time frame: Baseline up to 35 days post dose of study intervention

  14. Part B: Number of Participants With Clinical Laboratory Abnormalities

    Time frame: Baseline up to 4 days post dose of study intervention

  15. Part B: Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Time frame: Baseline up to 4 days post dose of study intervention

  16. Part B: Number of Participants With Change From Baseline in Electrocardiogram (ECG) Findings

    Time frame: Baseline up to 4 days post dose of study intervention

  17. Part B: Number of Participants With Clinically-Significant Change From Baseline in Physical Examination Findings

    Time frame: Baseline up to 35 days post dose of study intervention

  18. Part B: % of administered dose excreted in urine at each specified time interval

    Time frame: Days 1 to 11 at 24-hour intervals post-dose

  19. Part B: Total % of PF-07328948 dose recovered in urine

    Time frame: Days 1 to 11 at 24-hour intervals post-dose

  20. Part B: % of administered PF-07328948 dose excreted in feces at each specified time interval

    Time frame: Days 1 to 11 at 24-hour intervals post-dose

  21. Part B: Total % of PF-07328948 dose recovered in feces

    Time frame: Days 1 to 11 at 24-hour intervals post-dose

07

Study locations

2 sites
  • New Haven Clinical Research Unit
    New Haven, Connecticut 06511, United States
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
08

References and documents

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Jul 2024, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2023
First posted
Apr 11, 2023
StartActual
Apr 5, 2023
Primary completionActual
Jul 10, 2024
CompletionActual
Jul 10, 2024
Last update
Jul 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05807490
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 11, 2023
Start date
Apr 5, 2023
Primary completion
Jul 10, 2024
Completion
Jul 10, 2024
Last update
Jul 19, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07328948

Start the discussion